Patents by Inventor Francis Brasseur
Francis Brasseur has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8519109Abstract: Polypeptides comprising an unbroken sequence of amino acids from SEQ. ID. NO. 1 or 2, with an ability to complex with a major histocompatibility complex molecule type HLA-A2, and preferably HLA-A2.1.Type: GrantFiled: February 3, 2009Date of Patent: August 27, 2013Assignee: Ludwig Institute for Cancer Research Ltd.Inventors: Lan-Qing Huang, Aline van Pel, Francis Brasseur, Etienne De Plaen, Thierry Boon-Falleur
-
Patent number: 7785881Abstract: This invention relates to isolated peptides derived from MAGE-C2, nucleic acid molecules that encode MAGE-C2 and the isolated peptides derived from MAGE-C2, expression vectors comprising the nucleic acid molecules, host cells transformed or transfected with the nucleic acid molecules or the expression vectors, and to tetramers comprising the peptides, HLA molecules, ?2 microglobulin and a first and second binding partner. This invention also relates to methods for using the peptides, nucleic acid molecules, expression vectors, tetramers and complexes of this invention as well as to cytolytic T cells which recognize the peptides in complex with an HLA molecule.Type: GrantFiled: January 29, 2008Date of Patent: August 31, 2010Assignee: Ludwig Institute for Cancer ResearchInventors: Aline Van Pel, Daniele Godelaine, Javier Carrasco, Francis Brasseur, Thierry Boon-Falleur
-
Publication number: 20090209034Abstract: Polypeptides comprising an unbroken sequence of amino acids from SEQ. ID. NO. 1 or 2, with an ability to complex with a major histocompatibility complex molecule type HLA-A2, and preferably HLA-A2.1.Type: ApplicationFiled: February 3, 2009Publication date: August 20, 2009Applicant: Ludwig Institute for Cancer Research Ltd.Inventors: Lan-Qing Huang, Aline Van Pel, Francis Brasseur, Etienne De Plaen, Thierry Boon-Falleur
-
Patent number: 7547439Abstract: Polypeptides comprising an unbroken sequence of amino acids from SEQ ID NO: 1 or 2, with an ability to complex with a major histocompatibility complex molecule type HLA-A2, and preferably HLA-A2.1.Type: GrantFiled: November 26, 1999Date of Patent: June 16, 2009Assignee: Ludwig Institute for Cancer ResearchInventors: Lan-Qing Huang, Aline Van Pel, Francis Brasseur, Etienne De Plaen, Thierry Boon
-
Publication number: 20080311652Abstract: This invention relates to isolated peptides derived from MAGE-C2, nucleic acid molecules that encode MAGE-C2 and the isolated peptides derived from MAGE-C2, expression vectors comprising the nucleic acid molecules, host cells transformed or transfected with the nucleic acid molecules or the expression vectors, and to tetramers comprising the peptides, HLA molecules, ?2 microglobulin and a first and second binding partner. This invention also relates to methods for using the peptides, nucleic acid molecules, expression vectors, tetramers and complexes of this invention as well as to cytolytic T cells which recognize the peptides in complex with an HLA molecule.Type: ApplicationFiled: January 29, 2008Publication date: December 18, 2008Inventors: Aline Van Pel, Daniele Godelaine, Javier Carrasco, Francis Brasseur, Thierry Boon-Falleur
-
Patent number: 7348007Abstract: This invention relates to isolated peptides derived from MAGE-C2, nucleic acid molecules that encode MAGE-C2 and the isolated peptides derived from MAGE-C2, expression vectors comprising the nucleic acid molecules, host cells transformed or transfected with the nucleic acid molecules or the expression vectors, and to tetramers comprising the peptides, HLA molecules, ?2 microglobulin and a first and second binding partner. This invention also relates to methods for using the peptides, nucleic acid molecules, expression vectors, tetramers and complexes of this invention as well as to cytolytic T cells which recognize the peptides in complex with an HLA molecule.Type: GrantFiled: January 28, 2005Date of Patent: March 25, 2008Assignee: Ludwig Institute for Cancer ResearchInventors: Aline Van Pel, Daniele Godelaine, Javier Carrasco, Francis Brasseur, Thierry Boon-Falleur
-
Publication number: 20050255553Abstract: This invention relates to isolated peptides derived from MAGE-C2, nucleic acid molecules that encode MAGE-C2 and the isolated peptides derived from MAGE-C2, expression vectors comprising the nucleic acid molecules, host cells transformed or transfected with the nucleic acid molecules or the expression vectors, and to tetramers comprising the peptides, HLA molecules, ?2 microglobulin and a first and second binding partner. This invention also relates to methods for using the peptides, nucleic acid molecules, expression vectors, tetramers and complexes of this invention as well as to cytolytic T cells which recognize the peptides in complex with an HLA molecule.Type: ApplicationFiled: January 28, 2005Publication date: November 17, 2005Applicant: Ludwig Institute of Cancer ResearchInventors: Aline Pel, Daniele Godelaine, Javier Carrasco, Francis Brasseur, Thierry Boon-Falleur
-
Patent number: 6897288Abstract: The invention provides antigenic peptides derived from MAGE-A12 polypeptides and presented by HLA molecules. Methods for diagnosis and treatment which involve the polypeptides also are provided.Type: GrantFiled: October 19, 2000Date of Patent: May 24, 2005Assignee: Ludwig Institute for Cancer ResearchInventors: Leonora Heidecker, Benoit van den Eynde, Thierry Boon-Falleur, Francis Brasseur
-
Patent number: 6392016Abstract: The invention relates to members of the MAGE-B family of nucleic acid molecules. These molecules differ from the previously described MAGE nucleic acid molecules in that members of the MAGE-Xp family do not hybridize to the previously identified MAGE sequences. Further, the members of the MAGE-B family are found on the Xp arm of the X chromosome rather than on the Xq chromosome, as was the case with the previously identified MAGE genes.Type: GrantFiled: November 18, 1999Date of Patent: May 21, 2002Assignee: Ludwig Institute for Cancer ResearchInventors: Christophe Lurquin, Francis Brasseur, Thierry Boon-Falleur
-
Patent number: 6387630Abstract: Methods for diagnosing multiple myeloma are disclosed. These methods are based upon the observation that tumor rejection antigen precursors are expressed in multiple myeloma. By assaying bone marrow samples, one can diagnose multiple myeloma, and also monitor the disease's progress. Therapeutic approaches to multiple myeloma are also disclosed.Type: GrantFiled: November 2, 2000Date of Patent: May 14, 2002Assignee: Ludwig Institute for Cancer ResearchInventors: Nicolas Van Baren, Francis Brasseur, Thierry Boon-Falleur
-
Patent number: 6221593Abstract: A correlation between expression of tumor rejection antigen precursor MAGE-10 and cancer has been discovered. The invention is a method for determining presence of cancer in a sample by determining expression of MAGE-10. This determination can be made via, e.g., an immunoassay, an oligonucleotide hybridization assay, or via other standard methodologies.Type: GrantFiled: October 30, 1998Date of Patent: April 24, 2001Assignee: Ludwig Institute for Cancer ResearchInventors: Thierry Boon-Falleur, Francis Brasseur, Donata Rimoldi, Etienne De Plaen
-
Patent number: 6210886Abstract: Methods for diagnosing multiple myeloma are disclosed. These methods are based upon the observation that tumor rejection antigen precursors are expressed in multiple myeloma. By assaying bone marrow samples, one can diagnose multiple myeloma, and also monitor the disease's progress. Therapeutic approaches to multiple myeloma are also disclosed.Type: GrantFiled: October 30, 1998Date of Patent: April 3, 2001Assignee: Ludwig Institute for Cancer ResearchInventors: Nicolas Van Baren, Francis Brasseur, Thierry Boon-Falleur
-
Patent number: 6165725Abstract: Methods for diagnosing multiple myeloma are disclosed. These methods are based upon the observation that tumor rejection antigen precursors are expressed in multiple myeloma. By assaying bone marrow samples, one can diagnose multiple myeloma, and also monitor the disease's progress. Therapeutic approaches of multiple myeloma are also disclosed.Type: GrantFiled: July 12, 1999Date of Patent: December 26, 2000Assignee: Ludwig Institute for Cancer ResearchInventors: Nicolas Van Baren, Francis Brasseur, Thierry Boon-Falleur
-
Patent number: 6017705Abstract: The invention relates to members of the MAGE-B family of nucleic acid molecules. These molecules differ from the previously described MAGE nucleic acid molecules in that members of the MAGE-Xp family do not hybridize to the previously identified MAGE sequences. Further, the members of the MAGE-B family are found on the Xp arm of the X chromosome rather than on the Xq chromosome, as was the case with the previously identified MASGE genes.Type: GrantFiled: April 25, 1997Date of Patent: January 25, 2000Assignee: Ludwig Institute for Cancer ResearchInventors: Christophe Lurquin, Francis Brasseur, Thierry Boon-Falleur
-
Patent number: 5985571Abstract: Methods for diagnosing multiple myeloma are disclosed. These methods are based upon the observation that tumor rejection antigen precursors are expressed in multiple myeloma. By assaying bone marrow samples, one can diagnose multiple myeloma, and also monitor the disease's progress. Therapeutic approaches of multiple myeloma are also disclosed.Type: GrantFiled: February 4, 1998Date of Patent: November 16, 1999Assignee: Ludwig Institute for Cancer ResearchInventors: Nicolas Van Baren, Francis Brasseur, Thierry Boon-Falleur
-
Method for determining lung adenocarcinomas by assaying for one or more of MAGE-1, MAGE-2 and MAGE-3
Patent number: 5763165Abstract: A method for determining lung adenocarcinomas is described. The method involves assaying for expression of a gene coding for at least one of tumor rejection antigen precursors MAGE-1, 2 and 3, or their expression product.Type: GrantFiled: March 10, 1994Date of Patent: June 9, 1998Assignee: Ludwig Institute for Cancer ResearchInventors: Thierry Boon-Falleur, Patrick Weynants, Bernard Lethe, Francis Brasseur, Marie Marchand, Charles DeSmet, Christophe Lurquin, Pierre van der Bruggen, Etienne DePlaen -
Patent number: 5763155Abstract: A method for determining lung adenocarcinomas is described. The method involves assaying for expression of a gene coding for at least one of tumor rejection antigen precursors MAGE-1, 2 and 3, or their expression product.Type: GrantFiled: May 10, 1996Date of Patent: June 9, 1998Assignee: Ludwig Institute For Cancer ResearchInventors: Thierry Boon-Falleur, P. Weynants, Bernard Lethe, Francis Brasseur, M. Marchand, Charles DeSmet, Christophe Lurquin, Pierre Van Der Bruggen, Etienne DePlaen
-
Patent number: 5759783Abstract: The invention involves assaying for possible presence of certain cancers, by screening a sample for a member of the MAGE-Xp family of genes. These cancers include testicular seminoma, non-small call lung carcinoma, melanoma, breast cancer, sarcoma, and leukemia.Type: GrantFiled: June 5, 1996Date of Patent: June 2, 1998Assignee: Ludwig Institute For Cancer ResearchInventors: Christophe Lurquin, Francis Brasseur, Thierry Boon-Falleur
-
Patent number: 5512444Abstract: A method for screening for bladder cancer by identifying expression of one or more of MAGE-1, MAGE-2, MAGE-3 and MAGE-4 is the disclosed invention. Expression can be determined by a number of methods, including nucleotide amplification assays.Type: GrantFiled: November 30, 1994Date of Patent: April 30, 1996Assignee: Ludwig Institute For Cancer ResearchInventors: Jean-Jacques Patard, Francis Brasseur, Thierry Boon-Falleur